Critical Contrast: Absci (NASDAQ:ABSI) and Black Diamond Therapeutics (NASDAQ:BDTX)Defense World · Oct 8, 2026
Reviewing Pliant Therapeutics (NASDAQ:PLRX) & Black Diamond Therapeutics (NASDAQ:BDTX)Defense World · Sep 11, 2026
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire · Sep 2, 2026
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire · Aug 5, 2026Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.20 | -$0.17 | Beat |
| May 7, 2026 | -$0.18 | -$0.16 | Beat |
| Mar 16, 2026 | -$0.18 | -$0.26 | Miss |
| Nov 6, 2025 | -$0.22 | -$0.15 | Beat |
| Aug 7, 2025 | -$0.25 | -$0.19 | Beat |
| May 12, 2025 | $0.02 | $0.98 | Beat |